Cargando…
Use of azurocidin (heparin binding protein) and interleukin-1ß as prognostic indicators in COVID-19 patients
Objective: Considering the published manuscripts on this subject, it is thought that IL-1B and azurocidin may be diagnostic and prognostic factors in severe COVID-19 disease. This study aimed to determine whether azurocidin and IL-1β are useful biomarkers and are associated with disease exacerbation...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152632/ http://dx.doi.org/10.1177/1721727X221105129 |
_version_ | 1784717689301762048 |
---|---|
author | Akın Şen, İrem Karaşahin, Ömer Şebin, Engin Şen, Cem |
author_facet | Akın Şen, İrem Karaşahin, Ömer Şebin, Engin Şen, Cem |
author_sort | Akın Şen, İrem |
collection | PubMed |
description | Objective: Considering the published manuscripts on this subject, it is thought that IL-1B and azurocidin may be diagnostic and prognostic factors in severe COVID-19 disease. This study aimed to determine whether azurocidin and IL-1β are useful biomarkers and are associated with disease exacerbation in patients needing advanced treatment options. Material and Method: Our study was performed retrospectively. The data of a total of 291 patients followed in the hospital due to COVID-19 were collected. Among these patients, 66 randomly selected patients were included in this study. The control group consisted of 24 healthy individuals referred to the infectious disease outpatient clinic who weren’t no diagnosis of COVID-19 infection or any other infection. After the samples were taken into tubes without anticoagulant, they were kept at room temperature for 30 min. Afterwards, it was centrifuged at 1000xg for 15 min at +4° according to the instructions of the ELISA kit we used. The remaining serum was transferred to Eppendorf tubes and stored at −80° throughout this study. Results: A statistically significant strong positive correlation was determined between IL1β and azurocidin. A statistically significant weak positive correlation was found between IL1β and CRP, ferritin and neutrophil count, weak negative correlation with albumin, and moderately strong positive correlation with leukocyte count. Moreover, a statistically significant weak positive correlation was found between azurucidin and CRP, ferritin, and neutrophil counts. Conclusion: Azurocidin and IL-1β may serve as a potential therapeutic target for patients at risk of developing systemic multi-organ failure, with improved patient prognosis and prevention of death in severely ill patients. Although these results may contribute to the improvement of the follow-up and treatment of the patients and reduce mortality rates, there is a need for randomized controlled studies with a larger number of patients to be performed in the future. |
format | Online Article Text |
id | pubmed-9152632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-91526322022-05-31 Use of azurocidin (heparin binding protein) and interleukin-1ß as prognostic indicators in COVID-19 patients Akın Şen, İrem Karaşahin, Ömer Şebin, Engin Şen, Cem European Journal of Inflammation Original Research Article Objective: Considering the published manuscripts on this subject, it is thought that IL-1B and azurocidin may be diagnostic and prognostic factors in severe COVID-19 disease. This study aimed to determine whether azurocidin and IL-1β are useful biomarkers and are associated with disease exacerbation in patients needing advanced treatment options. Material and Method: Our study was performed retrospectively. The data of a total of 291 patients followed in the hospital due to COVID-19 were collected. Among these patients, 66 randomly selected patients were included in this study. The control group consisted of 24 healthy individuals referred to the infectious disease outpatient clinic who weren’t no diagnosis of COVID-19 infection or any other infection. After the samples were taken into tubes without anticoagulant, they were kept at room temperature for 30 min. Afterwards, it was centrifuged at 1000xg for 15 min at +4° according to the instructions of the ELISA kit we used. The remaining serum was transferred to Eppendorf tubes and stored at −80° throughout this study. Results: A statistically significant strong positive correlation was determined between IL1β and azurocidin. A statistically significant weak positive correlation was found between IL1β and CRP, ferritin and neutrophil count, weak negative correlation with albumin, and moderately strong positive correlation with leukocyte count. Moreover, a statistically significant weak positive correlation was found between azurucidin and CRP, ferritin, and neutrophil counts. Conclusion: Azurocidin and IL-1β may serve as a potential therapeutic target for patients at risk of developing systemic multi-organ failure, with improved patient prognosis and prevention of death in severely ill patients. Although these results may contribute to the improvement of the follow-up and treatment of the patients and reduce mortality rates, there is a need for randomized controlled studies with a larger number of patients to be performed in the future. SAGE Publications 2022-05-30 /pmc/articles/PMC9152632/ http://dx.doi.org/10.1177/1721727X221105129 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Article Akın Şen, İrem Karaşahin, Ömer Şebin, Engin Şen, Cem Use of azurocidin (heparin binding protein) and interleukin-1ß as prognostic indicators in COVID-19 patients |
title | Use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in COVID-19 patients |
title_full | Use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in COVID-19 patients |
title_fullStr | Use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in COVID-19 patients |
title_full_unstemmed | Use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in COVID-19 patients |
title_short | Use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in COVID-19 patients |
title_sort | use of azurocidin (heparin binding protein) and interleukin-1ß as
prognostic indicators in covid-19 patients |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152632/ http://dx.doi.org/10.1177/1721727X221105129 |
work_keys_str_mv | AT akınsenirem useofazurocidinheparinbindingproteinandinterleukin1ßasprognosticindicatorsincovid19patients AT karasahinomer useofazurocidinheparinbindingproteinandinterleukin1ßasprognosticindicatorsincovid19patients AT sebinengin useofazurocidinheparinbindingproteinandinterleukin1ßasprognosticindicatorsincovid19patients AT sencem useofazurocidinheparinbindingproteinandinterleukin1ßasprognosticindicatorsincovid19patients |